Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) revealed on Monday that it has opened the first clinical site for its Phase I trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (R/R AML) in adults. Patient recruitment has now commenced.
The trial, designed as a dose-escalation study, aims to evaluate the safety profile of HG-CT-1 in R/R AML patients. Key secondary objectives include assessing the therapy's impact on efficacy, overall survival (OS), progression-free survival (PFS), and duration of response (DoR) in patients who achieve clinical responses.
AML is a particularly aggressive form of leukemia with poor survival rates, and existing treatments are limited. HG-CT-1 offers a promising alternative, harnessing CAR-T therapy to modify a patient's T-cells to target cancer cells.
The initiation of this trial marks a significant milestone for Hemogenyx Pharmaceuticals, advancing its lead asset into clinical testing at a renowned cancer research institution. The company is headquartered in London and has US operations in New York City, focusing on innovative treatments for blood and autoimmune diseases.
CRISM Therapeutics advances clinical trial for ChemoSeed
Eli Lilly reveals positive Phase two results for lepodisiran
Dupixent receives approval in Japan as first biologic for COPD treatment
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
Spyre Therapeutics starts dosing in Phase 1 clinical trial of SPY003
IASO Biotherapeutics receives Macau approval for equecabtagene autoleucel NDA
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing